{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:12:24Z","timestamp":1790190744486,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s40266-015-0297-2","type":"journal-article","created":{"date-parts":[[2015,9,12]],"date-time":"2015-09-12T08:56:04Z","timestamp":1442048164000},"page":"689-697","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Treatment of Myasthenia Gravis in the Aged"],"prefix":"10.1007","volume":"32","author":[{"given":"Nuha M.","family":"Alkhawajah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Oger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,12]]},"reference":[{"issue":"5989","key":"297_CR1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/bmj.4.5989.152","volume":"4","author":"CW Havard","year":"1975","unstructured":"Havard CW. Diseases of the central nervous system. Myasthenia gravis. Br Med J. 1975;4(5989):152\u20134.","journal-title":"Br Med J."},{"issue":"11","key":"297_CR2","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/j.1532-5415.2000.tb02635.x","volume":"48","author":"A Evoli","year":"2000","unstructured":"Evoli A, Batocchi AP, Minisci C, Di Schino C, Tonali P. Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr Soc. 2000;48(11):1442\u20138.","journal-title":"J Am Geriatr Soc."},{"issue":"17","key":"297_CR3","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.0b013e318217e735","volume":"76","author":"Z Pakzad","year":"2011","unstructured":"Pakzad Z, Aziz T, Oger J. Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada. Neurology. 2011;76(17):1526\u20138. doi: 10.1212\/WNL.0b013e318217e735 .","journal-title":"Neurology."},{"key":"297_CR4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1196\/annals.1405.040","volume":"1132","author":"JA Aarli","year":"2008","unstructured":"Aarli JA. Myasthenia gravis in the elderly: Is it different? Ann N Y Acad Sci. 2008;1132:238\u201343. doi: 10.1196\/annals.1405.040 .","journal-title":"Ann N Y Acad Sci."},{"issue":"14","key":"297_CR5","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1001\/jama.1953.02940310038009","volume":"153","author":"RS Schwab","year":"1953","unstructured":"Schwab RS, Leland CC. Sex and age in myasthenia gravis as critical factors in incidence and remission. J Am Med Assoc. 1953;153(14):1270\u20133.","journal-title":"J Am Med Assoc."},{"issue":"7","key":"297_CR6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","volume":"16","author":"M Benatar","year":"2006","unstructured":"Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord. 2006;16(7):459\u201367. doi: 10.1016\/j.nmd.2006.05.006 .","journal-title":"Neuromuscul Disord."},{"key":"297_CR7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cca.2015.01.042","volume":"444","author":"J Oger","year":"2015","unstructured":"Oger J, Frykman H. An update on laboratory diagnosis in myasthenia gravis. Clin Chim Acta. 2015;444:126\u201331. doi: 10.1016\/j.cca.2015.01.042 .","journal-title":"Clin Chim Acta."},{"issue":"11","key":"297_CR8","doi-asserted-by":"crossref","first-page":"e80695","DOI":"10.1371\/journal.pone.0080695","volume":"8","author":"I Koneczny","year":"2013","unstructured":"Koneczny I, Cossins J, Waters P, Beeson D, Vincent A. MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters. PLoS One. 2013;8(11):e80695. doi: 10.1371\/journal.pone.0080695 .","journal-title":"PLoS One."},{"issue":"8","key":"297_CR9","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/01.wnl.0000254620.45529.97","volume":"68","author":"F Deymeer","year":"2007","unstructured":"Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaroglu P, Ozdemir C, et al. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis. Neurology. 2007;68(8):609\u201311. doi: 10.1212\/01.wnl.0000254620.45529.97 .","journal-title":"Neurology."},{"issue":"1","key":"297_CR10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mus.20069","volume":"30","author":"L Zhou","year":"2004","unstructured":"Zhou L, McConville J, Chaudhry V, Adams RN, Skolasky RL, Vincent A, et al. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve. 2004;30(1):55\u201360. doi: 10.1002\/mus.20069 .","journal-title":"Muscle Nerve."},{"issue":"8","key":"297_CR11","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/jnnp.2004.052415","volume":"76","author":"D Lavrnic","year":"2005","unstructured":"Lavrnic D, Losen M, Vujic A, De Baets M, Hajdukovic LJ, Stojanovic V, et al. The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry. 2005;76(8):1099\u2013102. doi: 10.1136\/jnnp.2004.052415 .","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"5","key":"297_CR12","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/jnnp.2004.043125","volume":"76","author":"Y Nemoto","year":"2005","unstructured":"Nemoto Y, Kuwabara S, Misawa S, Kawaguchi N, Hattori T, Takamori M, et al. Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry. 2005;76(5):714\u20138. doi: 10.1136\/jnnp.2004.043125 .","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"1","key":"297_CR13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/s-2004-829589","volume":"24","author":"A Vincent","year":"2004","unstructured":"Vincent A, McConville J, Farrugia ME, Newsom-Davis J. Seronegative myasthenia gravis. Semin Neurol. 2004;24(1):125\u201333. doi: 10.1055\/s-2004-829589 .","journal-title":"Semin Neurol"},{"issue":"12","key":"297_CR14","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","volume":"60","author":"DB Sanders","year":"2003","unstructured":"Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60(12):1978\u201380.","journal-title":"Neurology."},{"issue":"4","key":"297_CR15","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","volume":"55","author":"J McConville","year":"2004","unstructured":"McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol. 2004;55(4):580\u20134. doi: 10.1002\/ana.20061 .","journal-title":"Ann Neurol."},{"issue":"5","key":"297_CR16","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/mus.20854","volume":"36","author":"KH Chan","year":"2007","unstructured":"Chan KH, Lachance DH, Harper CM, Lennon VA. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve. 2007;36(5):651\u20138. doi: 10.1002\/mus.20854 .","journal-title":"Muscle Nerve."},{"issue":"4","key":"297_CR17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","volume":"69","author":"B Zhang","year":"2012","unstructured":"Zhang B, Tzartos JS, Belimezi M, Ragheb S, Bealmear B, Lewis RA, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol. 2012;69(4):445\u201351. doi: 10.1001\/archneurol.2011.2393 .","journal-title":"Arch Neurol."},{"issue":"7","key":"297_CR18","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/JTO.0b013e3181a4b8e0","volume":"4","author":"CB Falkson","year":"2009","unstructured":"Falkson CB, Bezjak A, Darling G, Gregg R, Malthaner R, Maziak DE, et al. The management of thymoma: a systematic review and practice guideline. J Thorac Oncol. 2009;4(7):911\u20139.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"297_CR19","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/jnnp.74.8.1105","volume":"74","author":"A Vincent","year":"2003","unstructured":"Vincent A, Clover L, Buckley C, Grimley Evans J, Rothwell PM, UK Myasthenia Gravis Survey. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry. 2003;74(8):1105\u20138.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"4","key":"297_CR20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamaneurol.2014.4103","volume":"72","author":"AE Renton","year":"2015","unstructured":"Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA, et al. A genome-wide association study of myasthenia gravis. JAMA Neurol. 2015;72(4):396\u2013404. doi: 10.1001\/jamaneurol.2014.4103 .","journal-title":"JAMA Neurol."},{"issue":"1","key":"297_CR21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/ene.12599","volume":"22","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Nacu A, Andersen JB, Owe JF. Myasthenia gravis and risks for comorbidity. Eur J Neurol. 2015;22(1):17\u201323. doi: 10.1111\/ene.12599 .","journal-title":"Eur J Neurol."},{"issue":"6","key":"297_CR22","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.semarthrit.2013.12.005","volume":"43","author":"JJ Paik","year":"2014","unstructured":"Paik JJ, Corse AM, Mammen AL. The co-existence of myasthenia gravis in patients with myositis: a case series. Semin Arthritis Rheum. 2014;43(6):792\u20136. doi: 10.1016\/j.semarthrit.2013.12.005 .","journal-title":"Semin Arthritis Rheum."},{"issue":"3","key":"297_CR23","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/mus.20935","volume":"37","author":"AR Punga","year":"2008","unstructured":"Punga AR, Sawada M, Stalberg EV. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis. Muscle Nerve. 2008;37(3):300\u20137. doi: 10.1002\/mus.20935 .","journal-title":"Muscle Nerve."},{"issue":"3","key":"297_CR24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","volume":"15","author":"RM Pascuzzi","year":"1984","unstructured":"Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984;15(3):291\u20138. doi: 10.1002\/ana.410150316 .","journal-title":"Ann Neurol."},{"key":"297_CR25","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1749-6632.1998.tb11017.x","volume":"841","author":"G Slesak","year":"1998","unstructured":"Slesak G, Melms A, Gerneth F, Sommer N, Weissert R, Dichgans J. Late-onset myasthenia gravis. Follow-up of 113 patients diagnosed after age 60. Ann N Y Acad Sci. 1998;841:777\u201380.","journal-title":"Ann N Y Acad Sci."},{"issue":"6","key":"297_CR26","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998;50(6):1778\u201383.","journal-title":"Neurology."},{"issue":"6","key":"297_CR27","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0960-8966(91)90005-D","volume":"1","author":"JB Kuks","year":"1991","unstructured":"Kuks JB, Djojoatmodjo S, Oosterhuis HJ. Azathioprine in myasthenia gravis: observations in 41 patients and a review of literature. Neuromuscul Disord. 1991;1(6):423\u201331.","journal-title":"Neuromuscul Disord."},{"issue":"12","key":"297_CR28","first-page":"1401","volume":"57","author":"A Natekar","year":"2011","unstructured":"Natekar A, Pupco A, Bozzo P, Koren G. Safety of azathioprine use during pregnancy. Can Fam Physician. 2011;57(12):1401\u20132.","journal-title":"Can Fam Physician."},{"issue":"12","key":"297_CR29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","volume":"316","author":"RS Tindall","year":"1987","unstructured":"Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987;316(12):719\u201324. doi: 10.1056\/NEJM198703193161205 .","journal-title":"N Engl J Med."},{"key":"297_CR30","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1196\/annals.1405.000","volume":"1132","author":"JM Ponseti","year":"2008","unstructured":"Ponseti JM, Gamez J, Azem J, Lopez-Cano M, Vilallonga R, Armengol M. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann N Y Acad Sci. 2008;1132:254\u201363. doi: 10.1196\/annals.1405.000 .","journal-title":"Ann N Y Acad Sci."},{"issue":"7","key":"297_CR31","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","volume":"17","author":"GO Skeie","year":"2010","unstructured":"Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17(7):893\u2013902. doi: 10.1111\/j.1468-1331.2010.03019.x .","journal-title":"Eur J Neurol."},{"issue":"6","key":"297_CR32","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312374.95186.cc","volume":"71","author":"DB Sanders","year":"2008","unstructured":"Sanders DB, McDermott M, Thornton C, Tawil R, Barohn RJ, Jackson C, et al. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71(6):394\u20139. doi: 10.1212\/01.wnl.0000312373.67493.7f .","journal-title":"Neurology."},{"issue":"6","key":"297_CR33","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","volume":"71","author":"DB Sanders","year":"2008","unstructured":"Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008;71(6):400\u20136. doi: 10.1212\/01.wnl.0000312374.95186.cc .","journal-title":"Neurology."},{"key":"297_CR34","first-page":"CD002277","volume":"12","author":"P Gajdos","year":"2012","unstructured":"Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2012;12:CD002277. doi: 10.1002\/14651858.CD002277.pub4 .","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"297_CR35","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/jca.21220","volume":"27","author":"EM Abdel-Rahman","year":"2012","unstructured":"Abdel-Rahman EM, Hayes J, Balogun RA. Therapeutic plasma exchange in the elderly: experience at a tertiary center. J Clin Apher. 2012;27(3):108\u201311. doi: 10.1002\/jca.21220 .","journal-title":"J Clin Apher."},{"issue":"10","key":"297_CR36","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00277-004-0895-2","volume":"83","author":"D Hefer","year":"2004","unstructured":"Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature. Ann Hematol. 2004;83(10):661\u20135. doi: 10.1007\/s00277-004-0895-2 .","journal-title":"Ann Hematol."},{"issue":"4","key":"297_CR37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amsu.2014.09.001","volume":"3","author":"JK Liu","year":"2014","unstructured":"Liu JK. The history of monoclonal antibody development - Progress, remaining challenges and future innovations. Ann Med Surg (Lond). 2014;3(4):113\u20136. doi: 10.1016\/j.amsu.2014.09.001 .","journal-title":"Ann Med Surg (Lond)."},{"issue":"9","key":"297_CR38","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/aps.2010.120","volume":"31","author":"J Li","year":"2010","unstructured":"Li J, Zhu Z. Research and development of next generation of antibody-based therapeutics. Acta Pharmacol Sin. 2010;31(9):1198\u2013207. doi: 10.1038\/aps.2010.120 .","journal-title":"Acta Pharmacol Sin."},{"issue":"9","key":"297_CR39","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/acr.22314","volume":"66","author":"S Payet","year":"2014","unstructured":"Payet S, Soubrier M, Perrodeau E, Bardin T, Cantagrel A, Combe B, et al. Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry. Arthritis Care Res (Hoboken). 2014;66(9):1289\u201395.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"297_CR40","author":"R Iorio","year":"2014","unstructured":"Iorio R, Damato V, Alboini PE, Evoli A. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2014;. doi: 10.1007\/s00415-014-7532-3 .","journal-title":"J Neurol."},{"issue":"6","key":"297_CR41","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/jnnp.2010.220475","volume":"82","author":"S Blum","year":"2011","unstructured":"Blum S, Gillis D, Brown H, Boyle R, Henderson R, Heyworth-Smith D, et al. Use and monitoring of low dose rituximab in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011;82(6):659\u201363. doi: 10.1136\/jnnp.2010.220475 .","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"5","key":"297_CR42","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/mus.23412","volume":"46","author":"N Collongues","year":"2012","unstructured":"Collongues N, Casez O, Lacour A, Tranchant C, Vermersch P, de Seze J, et al. Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. Muscle Nerve. 2012;46(5):687\u201391. doi: 10.1002\/mus.23412 .","journal-title":"Muscle Nerve."},{"issue":"2","key":"297_CR43","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1468-1331.2008.02399.x","volume":"16","author":"C Lebrun","year":"2009","unstructured":"Lebrun C, Bourg V, Tieulie N, Thomas P. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol. 2009;16(2):246\u201350. doi: 10.1111\/j.1468-1331.2008.02399.x .","journal-title":"Eur J Neurol."},{"issue":"1","key":"297_CR44","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","volume":"48","author":"JF Howard Jr","year":"2013","unstructured":"Howard JF Jr, Barohn RJ, Cutter GR, Freimer M, Juel VC, Mozaffar T, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013;48(1):76\u201384. doi: 10.1002\/mus.23839 .","journal-title":"Muscle Nerve."},{"issue":"4","key":"297_CR45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/CND.0000000000000034","volume":"15","author":"NJ Silvestri","year":"2014","unstructured":"Silvestri NJ, Wolfe GI. Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis. 2014;15(4):167\u201378. doi: 10.1097\/CND.0000000000000034 .","journal-title":"J Clin Neuromuscul Dis."},{"issue":"5","key":"297_CR46","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","volume":"18","author":"C Bossen","year":"2006","unstructured":"Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol. 2006;18(5):263\u201375. doi: 10.1016\/j.smim.2006.04.006 .","journal-title":"Semin Immunol."},{"issue":"9767","key":"297_CR47","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721\u201331. doi: 10.1016\/S0140-6736(10)61354-2 .","journal-title":"Lancet."},{"issue":"5","key":"297_CR48","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archneurol.2009.28","volume":"66","author":"J Strober","year":"2009","unstructured":"Strober J, Cowan MJ, Horn BN. Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis. Arch Neurol. 2009;66(5):659\u201361. doi: 10.1001\/archneurol.2009.28 .","journal-title":"Arch Neurol."},{"issue":"10","key":"297_CR49","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1093\/brain\/awq245","volume":"133","author":"O Grauer","year":"2010","unstructured":"Grauer O, Wolff D, Bertz H, Greinix H, Kuhl JS, Lawitschka A, et al. Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Brain. 2010;133(10):2852\u201365. doi: 10.1093\/brain\/awq245 .","journal-title":"Brain"},{"issue":"5","key":"297_CR50","doi-asserted-by":"crossref","first-page":"e96921","DOI":"10.1371\/journal.pone.0096921","volume":"9","author":"DT Hwee","year":"2014","unstructured":"Hwee DT, Kennedy A, Ryans J, Russell AJ, Jia Z, Hinken AC, et al. Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model. PLoS One. 2014;9(5):e96921. doi: 10.1371\/journal.pone.0096921 .","journal-title":"PLoS One."},{"issue":"2","key":"297_CR51","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s13311-015-0345-y","volume":"12","author":"DB Sanders","year":"2015","unstructured":"Sanders DB, Rosenfeld J, Dimachkie MM, Meng L, Malik FI, Tirasemtiv in Myasthenia Gravis Study G. A double-blinded, randomized, placebo-controlled trial to evaluate efficacy, safety, and tolerability of single doses of tirasemtiv in patients with acetylcholine receptor-binding antibody-positive myasthenia gravis. Neurotherapeutics. 2015;12(2):455\u201360. doi: 10.1007\/s13311-015-0345-y .","journal-title":"Neurotherapeutics."},{"issue":"5","key":"297_CR52","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jtcvs.2012.07.082","volume":"144","author":"G Marulli","year":"2012","unstructured":"Marulli G, Rea F, Melfi F, Schmid TA, Ismail M, Fanucchi O, et al. Robot-aided thoracoscopic thymectomy for early-stage thymoma: a multicenter European study. J Thorac Cardiovasc Surg. 2012;144(5):1125\u201330. doi: 10.1016\/j.jtcvs.2012.07.082 .","journal-title":"J Thorac Cardiovasc Surg."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-015-0297-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-015-0297-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-015-0297-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T12:03:37Z","timestamp":1567166617000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-015-0297-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["297"],"URL":"https:\/\/doi.org\/10.1007\/s40266-015-0297-2","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}